NEWS2022-12-16T11:56:40-05:00
NEWS
Keep up with South Rampart Pharma's latest developments

Safer Non-Opioid Pain Relief on the Horizon: SRP-001 Shows Promise in Phase 1 Trials

Health & Pharma
Safer Non-Opioid Pain Relief on the Horizon: SRP-001 Shows Promise in Phase 1 Trials
May 23, 2024

With FDA Fast Track designation, the new non-opioid pain medication SRP-001 shows promising Phase 1 trial results, offering a safer alternative for pain management. Unlike traditional painkillers, SRP-001 does not pose risks of abuse, liver, or kidney damage and effectively targets pain via AM404 in the brain’s PAG region.

Read more here

Novel Non-Addictive, Non-Toxic Painkiller Developed at LSU Health New Orleans

LSU Health New Orleans
Novel Non-Addictive, Non-Toxic Painkiller Developed at LSU Health New Orleans
May 16, 2024

LSU Health New Orleans announces the discovery and clinical advancement of a new non-opioid therapeutic candidate for treatment of acute, chronic, and neuropathic pain and migraine headaches which does not have the organ toxicity or addiction potential of other currently-available pain therapeutics.

Read more here

South Rampart Pharma Publishes SRP-001’s Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports

May 16, 2024

  • SRP-001 is a novel, non-opioid new chemical entity without abuse, liver, and kidney toxicities present in current pain medications
  • Publication introduces SRP-001 as a safer alternative to existing pain medications
  • SRP-001 triggers N-arachidonoylphenolamine (AM404) formation in the midbrain’s periaqueductal grey (PAG) region, a potent activator of TRPV1 that plays a crucial role in the brain’s response to pain
  • FDA awarded SRP-001 Fast Track designation for acute pain in October 2023
  • Phase 1 trial shows SRP-001 is safe and well-tolerated with favorable pharmacokinetics making it Phase 2-ready for the treatment of neuropathic pain, acute/chronic pain, and patients with acute migraine headaches.
  • A Phase 2 trial in acute pain will launch in the second half of 2024

NEW ORLEANS, May 16, 2024 (GLOBE NEWSWIRE) — South Rampart Pharma, Inc., today announced the publication of a paper in Scientific Reports describing the manner in which SRP-001 works

Read more here

Ochsner Health physician granted NIH Trailblazer Award

Eureka Alert!
Ochsner Health physician granted NIH Trailblazer Award
February 14, 2024

In response to the pressing need for new pain treatments during the opioid crisis, the National Institutes of Health (NIH) has honored Dr. Hernan Bazan, an Ochsner Health physician and John Ochsner Endowed Professor of Cardiovascular Innovation, with the 2024 NIH Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative® Director’s Trailblazer Award.

Read more here

South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and Acute Pain Trials

January 2, 2024

Phase 1 data demonstrate that SRP-001 exhibits an exceptionally strong safety and robust pharmacokinetic profile and is well-tolerated
Well-designed Phase 2 trials set to show statistical significance compared to placebo and positive control

 

New Orleans, LA, January 2, 2024 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company focused on developing innovative pain treatments, announced today that it has successfully completed a Phase 1 trial (NCT05484414). The Phase 1 randomized clinical trial (RCT) of SRP-001, a first-in-class analgesic targeting the midbrain’s PAG region, was a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and pharmacokinetics (PK) of SRP-001 in healthy subjects. Conducted in collaboration with Quotient Sciences in Miami, Florida, the trial’s completion marks a significant milestone, as SRP-001 has now received U.S. FDA Fast-Track designation, underscoring its potential in the safe and effective treatment of pain.

The demand for

Read more here

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

November 1, 2023

South Rampart’s Global Intellectual Property Portfolio Now Includes Patents in Key Markets: United States, Europe, Greater China, India, Japan, S. Korea, Australia, Canada, Brazil, Russia, and Mexico

 

New Orleans, LA, November 1, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company focused on developing innovative pain treatments,

announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

The patent, entitled “Compositions and methods for ameliorating pain,” encompasses the methods and composition of matter for a library of novel non-opioid small molecules devoid of liver toxicity for acute, chronic, and neuropathic pain. This includes the Company’s lead clinical candidate, SRP-001, which the U.S. FDA granted Fast Track designation for acute pain on October 9, 2023, and is ending Phase

Read more here

Global Business Report

Global Business Reports
Global Business Report
October 17, 2023

Can you give an overview of South Rampart Pharma and present SRP-001? South Rampart Pharma is a clinical-stage, phase 1 life science company developing a best-in-class new chemical entity (NCE), SRP-001, a non-opioid small molecule analogous to acetaminophen or paracetamol. The significant differentiator is that it does not have the liver toxicity of acetaminophen /paracetamol/Tylenol or the kidney toxicity of NSAIDs like ibuprofen.

Read more here

South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain

Oct. 12, 2023

The Fast Track designation accelerates SRP-001’s path to U.S. FDA submission for the treatment of acute pain

Enhanced time-to-market delivers a therapeutic alternative to habit-forming opioids and acetaminophen, the leading cause of acute liver failure in the U.S.

NEW ORLEANS, Oct. 12, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage biopharmaceutical company targeting the safer treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company for SRP-001 for the treatment of acute pain. SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain’s periaqueductal grey (PAG) region without liver and kidney toxicities. The Fast Track designation facilitates the development and expedites the review of new therapies for serious conditions, aiming to bring important new drugs to patients earlier and

Read more here

South Rampart Pharma to Participate in Upcoming Investor Events

October 10, 2023

 – BIO Investor Forum taking place on October 17-18, 2023 –

 – The 17th Annual Pain Therapeutics Summit taking place on October 19-20, 2023

 

New Orleans, LA, October 10, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company developing SRP-001, a first-in-class non-opioid candidate for the treatment of chronic and acute pain, today announced the Company’s executive team will be participating in the upcoming investor events throughout October 2023:

 

BIO Investor Forum (San Francisco, CA):

Date: October 17-18, 2023

Corporate Presentation Time: 2:15 PM ET, Oct. 17, 2023

Title: ‘‘SRP-001, A First-in-Class, Non-Opioid Analgesic Targeting Novel Pain Signaling Pathways in the Periaqueductal Grey Region: Phase 1 Interim Results & Comparative Efficacy.”

Panel Discussion: 5:00 PM ET, Oct. 17, 2023

Title: “Succeeding at Technology Transfer:  Best Practices for Industry-Academia Collaboration.”

Program: https://bif.bio.org/program

South Rampart’s Co-founder and CEO, Dr. Hernan Bazan, will present a Corporate

Read more here

South Rampart Pharma Awarded Second NIH Grant for Commercialization Readiness Pilot Program

Sept. 21, 2023

The NIH’s CRP Award Further Validates the Business Case and Commercial Opportunity of
SRP-001 as a First-in-Class Non-narcotic Analgesic for Acute and Chronic Pain

NEW ORLEANS, Sept. 21, 2023 — South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that it has been awarded The Commercialization Readiness Pilot Program (CRP) grant by the National Institute of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) for its application entitled ‘Novel non-narcotic analgesic for acute and chronic pain.’ This grant under award number 2SB1NS119103–04 propels select biotech firms towards market readiness, bolstering South Rampart’s mission to foster advancements in the safer treatment of pain management through novel non-narcotic solutions. Today’s announcement follows the Company’s earlier receipt of the NIH’s Fast-Track Small Business Technology Transfer (STTR) Commercialization

Read more here

South Rampart Pharma Announces First Patient Enrolled in Multiple Ascending Dose Portion of Ongoing Phase 1 ClinicalTrial

August 22, 2023

– SRP-001, a novel, non-opioid investigational drug that avoids the liver toxicity associated with acetaminophen, positioned to address the unmet medical need for non-toxic and non-addictive acute and chronic pain therapeutics –

– Data expected in 3Q 2023 –

New Orleans, LA, Aug 22, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the first patient of its Phase 1 trial, multiple ascending dose (MAD) study, has been dosed. The primary objective of the MAD study is to assess the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of oral SRP-001 to healthy male and female volunteers, with the primary endpoints being safety and tolerability by assessing adverse events (AEs), vital signs, electrocardiograms (ECGs), physical examinations, laboratory safety tests, and select PK/PD parameters. The trial is expected to be completed in

Read more here

South Rampart Pharma Further Expands Patent Portfolio for SRP-001 with Composition of Matter Patent in China

July 6, 2023

South Rampart’s global intellectual property portfolio now includes granted patents in the United States, China, India, Japan, Australia, Canada, Brazil, Russia, and Mexico

New Orleans, LA, July 6, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of SRP-001, South Rampart’s novel, non-opioid new chemical entity that avoids the liver toxicity associated with acetaminophen. The Company is currently developing SRP-001 for treating acute and chronic pain and is evaluating it in an ongoing Phase 1 trial. This patent, as well as other patents the Company has been granted and is currently pursuing, is a key part of South Rampart’s global intellectual property (IP) and patent strategy.

The Chinese Patent Office issued

Read more here

Warning About Potential Risks from Overuse of Acetaminophen with Karen Smith Catie’s Cause

Empowered Patient Podcast with Karen Jagoda
Warning About Potential Risks from Overuse of Acetaminophen with Karen Smith Catie’s Cause
June 5, 2023

Karen Smith is the Founder of Catie’s Cause, a nonprofit charity dedicated to building awareness about the safe use of over-the-counter pain medications. After the death of her daughter Catie from liver failure due to overuse of Tylenol, Karen founded this organization to shine a light on the unintended and intentional side effects of easy access to these medicines.

Read more here

Biotechnology Innovation Organization – I am BIO Podcast

Biotechnology Innovation Organization – I am BIO Podcast
Episode 80: Cracking the Code on Pain Relief
February 28, 2023

Imagine living with excruciating pain that prevents you from walking or doing the things most of us take for granted. We all experience pain, and 50 million people cope with chronic, debilitating pain. The market for pain therapies is estimated at $74 billion. And yet, investment in new pain and addiction treatments is falling short of what is needed, according to a new BIO report, which shows a 44% decrease in clinical drug programs for pain over the past five years. Our guests on this episode talk about the challenges of living with and treating pain, as well as research and development on new, non-addictive and safer pain therapies.

Read more here

BIO CEO 2023: Despite high prevalence of pain and addiction, clinical efforts drop, funding flat, BIO report finds

BioWorld
BIO CEO 2023: Despite high prevalence of pain and addiction, clinical efforts drop, funding flat, BIO report finds
Feb. 9, 2023

The Biotechnology Innovation Organization (BIO) found in a new study that 77% of clinical programs focused on pain
therapeutics five years ago are no longer active and that financings of companies working in the space are lackluster at
best.

Meanwhile, oncology companies, targeting an overall smaller market, have raised huge sums of venture capital (VC)
money, $9.7 billion in 2021 vs. pain and addiction companies’ $228 million.

Read more here

Focus and Fundamentals: CFO Strategies on the Journey to Commercialization

Pharmaceutical Executive
Focus and Fundamentals: CFO Strategies on the Journey to Commercialization
February 9, 2023

Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day.

On Dec. 1, 2022, a panel consisting of chief financial officers (CFOs) and other financial experts convened for a virtual roundtable to discuss the recent economic developments in the life sciences industry and how companies are adapting. The biopharmaceutical sector has not been immune to global economic challenges. After the COVID-19 pandemic generated a wave of new interest in the life sciences, the past year saw a retraction in the market.

Read more here

Founders Keepers podcast

Founders Keepers podcast
#35 Conference Special (2/2): Dr Hernan Bazan from South Rampart Pharma
February 9, 2023

Founded in 2016, South Rampart Pharma is a clinical-stage life science company dedicated to advancing the safe treatment of pain by developing new non-opioid small molecule solutions that lack the liver and kidney toxicity present in current pain medicines. The company’s lead program, SRP-001, is currently in a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics with data expected later this year in 2023.

Read more here

Panel Takes on Challenges in Pain Therapeutics at BIO CEO

BioSpace
Panel Takes on Challenges in Pain Therapeutics at BIO CEO
February 9, 2023

Finding long-term, non-addictive solutions to manage chronic pain in the U.S. has long been a challenge for biopharma. In thefallout from the opioid pandemic, physicians and researchers are scrambling for options.

Tuesday, a panel of experts took on stiff questions about pain/addiction therapeutics during a panel hosted by theBiotechnology Innovation Organizaion (BIO) in New York City.

Read more here

‘All hands on deck’ needed to address U.S. pain and addiction innovation

Bio.News
‘All hands on deck’ needed to address U.S. pain and addiction innovation
February 8, 2023

The number of new pain drugs in the development pipeline has slowed to a trickle and investment in addiction drugs is low, challenges addressed during an impassioned, collaborative panel, “Resetting the innovation landscape for pain and addiction therapeutics,” yesterday at BIO’s 2023 CEO and Investor Conference.

Panelists discussed potential solutions as they responded to BIO’s recent report, “The State of Innovation in Pain and Addiction,” which describes the issue in detail.

Read more here

South Rampart Pharma to Present at 2023 BIO CEO & Investor Conference

Jan. 31, 2023

Hernan Bazan, MD, FACS, CEO and Co-Founder, will provide a company update

Dr. Bazan will also participate in a panel on pain therapeutics innovation with a VP of Industry Research from BIO and Program Directors from NIH and the U.S. Pain Foundation

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative non-opioid medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at the BIO CEO & Investor Conference on Monday, February 6.

Dr. Bazan’s presentation will highlight the recent company developments on its novel non-opioid lead asset, ongoing pipeline progress, clinical trial updates and anticipated milestones. Details about the presentation are as follows:

Presenter: Hernan Bazan, MD, FACS,

Read more here

Scrip Asks…What Does 2023 Hold For Biopharma? Part2: M&A And Partnering

Scrip Pharma Intelligence
Scrip Asks…What Does 2023 Hold For Biopharma? Part2: M&A And Partnering
January 9, 2023

Hernan Bazan, CEO of South Rampart Pharma, which is developing small molecules for pain relief, also commented on the benefits of in-person get-togethers, although he acknowledged the perks of virtual interaction when it comes to partnering. “I think hybrid approaches will continue in 2023. Following the pandemic, my first in-person partnering meeting was BIO in June 2022 (San Diego), and there was palpable excitement to meet face-to-face. Though deals can be done virtually, personal interaction allows a connection to be made when technology and partnering tactics are discussed. Virtual meeting platforms allow for efficient use of time when doing more technical reviews,” he said.

“For these reasons, I feel the hybrid approach is here to stay. I think partnering through option license deals for promising technologies – particularly those with clinically

Read more here

Current Lack of Innovation in the Pain Space Hurts Society

MedCity News
Current Lack of Innovation in the Pain Space Hurts Society
December 22, 2022

The future towards the safer treatment of pain will come as biopharma, and investor communities appreciate the significant opportunities in supporting scientifically rigorous and clinically validated lead assets for the safer treatment of pain.

Current pain medications are addictive (opioids), or potentially damaging to the liver (acetaminophen/Tylenol or kidneys with substantial gastrointestinal toxicity (nonsteroidal anti-inflammatory drugs, NSAIDs).

Read more here

Tales From the 2022 Biotech VC Fundraising Trail

The Wall Street Journal
Tales From the 2022 Biotech VC Fundraising Trail
December 22, 2022

After the bonanza of 2021, life-sciences entrepreneurs reset their expectations as financing contracted

Biotechnology entrepreneurs recalibrated in 2022 as their financing options narrowed, a reversal from years in which life-sciences startups were flush with capital.
With just two weeks left in the year, U.S. biotechs had raked in $29.7 billion for 2022, compared with the record—$38.7 billion—deployed in all of 2021, according to market tracker PitchBook Data Inc.

Read more here

Wellbeing Checkup

Medical World News
Wellbeing Checkup
December 9, 2022

It is estimated that up to 20% of US adults are dealing with chronic pain and 8% of US Adults have high-impact chronic pain. Dr. Hernan Bazan discusses the issues associated with suffering from chronic pain and daily use of opioids, offers some insights on traditional pain relievers, and how the next generation of therapies in development need to be a safe, potential alternative from opioids.

Read more here

Non-toxic and addiction free: The promise of a new pain med

PharmaVoice
Non-toxic and addiction free: The promise of a new pain med
December 2, 2022

Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

Pain relief without toxicity or addiction could become a reality, and South Rampart Pharma’s father-son, surgeons-turned-entrepreneurs duo could hold the key. Dr. Hernan Bazan, CEO and co-founder of the clinical stage pain company, believes it’s on the right track to capitalize not only on a market that is predicted to be valued at $90 billion by 2026, but help the 20% of adults worldwide who suffer from chronic pain.

Read more here

South Rampart Pharma Announces Presentation at Arrowhead’s 16th Annual Pain Therapeutics Summit

Oct. 21, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at Arrowhead’s 16th Annual Pain Therapeutics Summit.

Taking place in Washington, DC, on November 14-15, 2022, the Pain Therapeutics Summit is the US’s premier conference covering pain research and emerging therapeutics. Leaders from the biopharmaceutical industry, academia, and the NIH attend the conference to learn about the latest advances in treating various kinds of pain and network with colleagues from industry, academia, clinical research organizations, and government.

Dr. Bazan’s presentation, “Overcoming the Liver Toxicity Associated with Acetaminophen Via a New Class of Small Molecule Non-Opioids,” will highlight the ongoing clinical development of novel non-opioid small molecule SRP-001 for the treatment

Read more here

South Rampart Pharma Issued Composition of Matter Patent for Novel Non-Toxic Treatment for Pain

Oct. 4, 2022

 New patent grant further secures South Rampart’s competitive position in next-generation and disruptive investigational drugs for acute pain –

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced the issuance of a composition of matter US patent No. 11,458,142 for its novel, non-opioid, and non-liver toxic treatments for pain. The issued patent covers a library of novel small molecules, including the Company’s lead program, SRP-001, which is currently being studied in a two-part randomized, double-blind, placebo-controlled study Phase 1 study evaluating safety, tolerability, and pharmacokinetics, with data expected early in 2023.

This issued patent adds to the Company’s growing patent portfolio, which includes ‘Compositions and methods for ameliorating pain and reducing fever’ US patent No. 11,007,199. The Composition of Matter patent issued today has been nationalized in key world markets. South

Read more here

South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant

Sept. 22, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that it received a Notice of Award from the National Institutes of Health (NIH) regarding Year 3 of its Small Business Technology Transfer (STTR) grant.

The NIH grant is entitled ‘Novel non-narcotic analgesic for acute and chronic pain.’ South Rampart Pharma will receive the Year 3 incremental Award of the $1.9M grant administered through the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), which will continue to help support the development of SRP-001, the Company’s lead drug candidate.

SRP-001 is a novel, non-opioid small molecule with the potential to overcome many risks associated with current pain medicines, including the liver toxicity of acetaminophen. Importantly, SRP-001 mirrors acetaminophen’s clinically validated mechanism of action while simultaneously muting the biological activity that causes liver toxicity. South Rampart Pharma is

Read more here

A New Pain Treatment Requires Accurate And Reliable Data, South Rampart Pharma on Featured on Clinical Leader piece.

Clinical Leader
A New Pain Treatment Requires Accurate And Reliable Data, South Rampart Pharma on Featured on Clinical Leader piece.
September 22, 2022

South Rampart Pharma aims to deliver a new, affordable treatment for pain that will avoid the issues with currently marketed products. Opioids are highly addictive; patients taking excessive amounts of acetaminophen can develop liver toxicity; and NSAID over-exposure risks kidney toxicity, gastrointestinal (GI) bleeding, and worsening of high blood pressure in patients with hypertension.

Read more here

South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain

Aug. 25, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that the Company will present a late-breaking abstract at the International Association for the Study of Pain (IASP) 2022 World Congress on Pain, which will take place on September 20-23, 2022, in Toronto, Canada.

The late-breaking presentation, entitled “Novel Non-Opioid Analgesic for Acute and Chronic Pain: From Discovery to Phase 1 Trial,” will chronicle the invention and development of SRP-001 (previously known aSRP-3D (DA)). Central to SRP-001’s therapeutic differentiation, this non-opioid investigational pain medication exhibits comparable, if not better, efficacy as similar approved drugs but notably does not exhibit their liver or kidney toxicity. South Rampart’s CEO and Co-founder, Hernan Bazan, MD, FACS, will deliver the presentation.

“I’m delighted to have this opportunity to showcase the groundbreaking work we’ve done with SRP-001,” commented Dr. Bazan. “Liver toxicity

Read more here

South Rampart Pharma Announces Appointment of Josh Blacher as Chief Financial Officer

Aug. 16, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced the appointment of Josh Blacher as the company’s Chief Financial Officer. In this capacity, Mr. Blacher will be responsible for the Company’s finance and accounting department, as well as launch a robust corporate development effort.

Mr. Blacher brings to South Rampart Pharma over twenty years of leadership experience in senior positions in the healthcare and capital markets sectors. Hernan Bazan, M.D., F.A.C.S., CEO and Co-Founder of South Rampart Pharma and The Endowed John Ochsner Professor of Surgery at the Ochsner Clinic, commented, “We are thrilled to welcome Josh to our team. Josh brings us a valuable combination of executing growth capital initiatives as well as strategic collaborations with biopharmaceutical partners.” Dr. Bazan continued, “As we ready for Phase 2 clinical trials of our novel non-opioid

Read more here

South Rampart Pharma Hopes to Develop Safer Pain Medications

Biz New Orleans
South Rampart Pharma Hopes to Develop Safer Pain Medications
June 14, 2022

South Rampart Pharma, a clinical-stage life science company advancing medications for the treatment of pain and fever, announced it achieved milestones outlined in the Phase I portion of its Small Business Technology Transfer (STTR) grant (1R42NS119103) received from the National Institutes of Health (NIH) and advanced to the Phase II portion of its NIH grant. The “fast-track” combined Phase I/II award provides for $1.9 million of funding to support the ongoing clinical development of the company’s lead small molecule, SRP-3D (DA), a novel non-opioid therapeutic candidate. South Rampart Pharma currently is completing the single ascending dose phase of the Phase 1 clinical trial of SRP-3D (DA) and remains on track to report topline results from the study in the third quarter of 2022.

Read more here

South Rampart Pharma Achieves Development Milestone and Advances to Phase II of Active NIH Fast-Track STTR Commercialization Award

May 4, 2022

$1.9 million NIH fast-track STTR grant fuels next stage of clinical program dedicated to the development of a novel non-opioid approach to pain management

Lead program SRP-3D (DA) advances in ongoing Phase 1 clinical trial with data expected in the third quarter of 2022

 

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced it achieved milestones outlined in the Phase I portion of its Small Business Technology Transfer (STTR) grant (1R42NS119103) received from the National Institutes of Health (NIH) and advanced to the Phase II portion of its NIH grant. The ‘fast-track’ combined Phase I/II award provides for $1.9 million of funding to support the ongoing clinical development of the Company’s lead small molecule, SRP-3D (DA), a novel non-opioid therapeutic candidate. South Rampart Pharma currently is completing the single

Read more here

South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)

March 23, 2022

SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications

Potential to address the significant unmet need for new, safe, effective, and non-opioid pain medications

Development program funded by the National Institutes of Health (NIH) through a Small Business Technology Transfer (STTR) Fast Track Grant

Topline results expected Q3 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company focused on advancing innovative medications for the treatment of pain and fever, announced today patient enrollment and dosing in its Phase 1 study evaluating SRP-3D (DA) for pain is underway.

“We are committed to improving the lives of people suffering from acute, chronic, or neuropathic pain by developing a new class of small molecule, non-opioid pain medicines. To date, SRP-3D (DA) has shown promising efficacy in reducing both pain and fever while lacking the liver and kidney toxicity associated

Read more here

South Rampart Pharma Invited to Participate in 2021 NIH Innovation Conference & Life Sciences Summit

NOLABA News
South Rampart Pharma Invited to Participate in 2021 NIH Innovation Conference & Life Sciences Summit
August 20, 2021

Exciting news for local company South Pharma! They’ve been selected to participate in the 2021 NIH Innovation Conference (NIC – a half-day, virtual event on Monday, Oct. 4) and Life Science Summit (LSS – a two-day virtual event Tuesday, Nov. 9 and Wednesday, Nov. 10) that connects innovation, capital, and industry.

See Q&A below with Company co-founder Dr. Hernan A. Bazan.

How do you feel about being selected to participate in the NIH Conference?

It’s obviously a great recognition of the hard science behind the venture.  In 2020 we were able to compete with top groups from the major academic and entrepreneurial centers around the U.S. and an NIH (NINDS) Commercialization grant we submitted was scored highly and was funded.  The NIH leadership has seen the progress in the past year and has

Read more here

LSU HSCNO Spin-Out Awarded $1.9M in STTR Fast Track Funding

LSU Health New Orleans
LSU HSCNO Spin-Out Awarded $1.9M in STTR Fast Track Funding
September 28, 2020

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer (STTR) grant to South Rampart Pharma. The New Orleans life science company is developing a new class of non-opioid medicines to relieve pain and reduce fever discovered at and licensed from LSU Health New Orleans, its formal collaborating research institution.

Read more here

NIH Awards $1.9 million STTR Grant to Fast Track New Class of Non-Opioid Pain Relievers

News-Medical.Net
NIH Awards $1.9 million STTR Grant to Fast Track New Class of Non-Opioid Pain Relievers
September 25, 2020

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer (STTR) grant to South Rampart Pharma. The New Orleans life science company is developing a new class of non-opioid medicines to relieve pain and reduce fever discovered at and licensed from LSU Health New Orleans, its formal collaborating research institution.

Read more here

NIH STTR Grant To Fast Track New Class Of Pain Reliever Without Addiction Or Toxicity

Sep 25, 2020

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer (STTR) grant to South Rampart Pharma. The New Orleans life science company is developing a new class of non-opioid medicines to relieve pain and reduce fever discovered at and licensed from LSU Health New Orleans, its formal collaborating research institution.

The grant will fund late-stage, pre-clinical development of the new analgesic/antipyretic and will also support continued collaboration with LSU Health New Orleans Neuroscience Center of Excellence on pain mechanisms. A paper describing the patented new drug was recently published in the European Journal of Medicinal Chemistry.

“The safe treatment of acute and chronic pain is one of the most prevalent and costly public health issues worldwide,” said Hernan Bazan, MD, DFSVS, FACS, CEO and co-founder of South Rampart Pharma, and Professor of Surgery at the Ochsner

Read more here

Novel Analgesic for Pain Relief Lacks Liver Toxicity

PainRelief.com
Novel Analgesic for Pain Relief Lacks Liver Toxicity
July 24, 2020

Thank you for your kind invitation and opportunity to commend on our paper in press in the European Journal of Medicinal Chemistry entitled ‘A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis.’ This is the culmination of a multi-disciplinary effort involving investigators from the United States in Spain in search for a solution to the problem of treating pain more safely.

Read more here

Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects

AJMC
Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects
July 20, 2020

The coronavirus disease 2019 pandemic presents a new challenge: patients have severe flu-like symptoms, but the virus can also cause renal failure. Doctors and patients need analgesics that go easy on the liver and kidneys but are not addictive, and this week researchers at LSU Health New Orleans Neuroscience Center of Excellence announced they have discovered a new class of drugs that can do the job.

Read more here

South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication

July 10, 2020

South Rampart Pharma, LLC (“South Rampart” or “the Company”), a company committed to improving the lives of people suffering from pain by developing a new class of non-opioid pain medicines, today announced a peer-reviewed publication detailing the identification and characterization of a new class of compounds able to reduce pain and fever without abuse potential or the liver and kidney toxicity associated with over the counter pain medicines such as acetaminophen. The paper, published in the European Journal of Medicinal Chemistry, is available as open access and entitled, “A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis1.

“We are currently working to finalize the preclinical data package necessary to submit our lead molecule for the first Investigational New Drug (IND) application by the third quarter of 2020, followed by the rapid initiation of Phase 1 clinical trials to evaluate safety. Ongoing preclinical studies have

Read more here

South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication

BioSpace
South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication
July 14, 2020

South Rampart Pharma, LLC (“South Rampart” or “the Company”), a company committed to improving the lives of people suffering from pain by developing a new class of non-opioid pain medicines, today announced a peer-reviewed publication detailing the identification and characterization of a new class of compounds able to reduce pain and fever without abuse potential or the liver and kidney toxicity associated with over the counter pain medicines such as acetaminophen.

Read more here

Research Roundup: COVID-19 Immunity, Stomach Acid Susceptibility and More

BioSpace
Research Roundup: COVID-19 Immunity, Stomach Acid Susceptibility and More
July 10, 2020

Investigators at LSU Health New Orleans Neuroscience Center of Excellence identified a new class of pipeline drugs to relieve pain and reduce fever. Furthermore, they appear to have decreased risk of addiction or damage to the liver or kidneys. In two models, the drugs, which are similar to acetaminophen, but do not appear to damage the liver or kidneys, decreased pain and reduced fever. The intellectual property has been licensed from LSU to the life science startup South Rampart Pharma, which is working to develop the drug in late preclinical development.

Read more here

Novel class of non-addictive analgesics demonstrate safety in animals

Drug Target Review
Novel class of non-addictive analgesics demonstrate safety in animals
July 7, 2020

To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen. Acute and chronic pain management is a growing global health burden. With the opioid epidemic still on the rise, and nephro- and hepatotoxicity linked to prolonged use of non-narcotic pain medications, novel analgesics (pain killers) are desperately needed.

Read more here

A new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage

Innovation Toronto
A new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage
July 6, 2020

Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys. The research is published online in the European Journal of Medicinal Chemistry.

Read more here

LSU Health New Orleans discovers new class of safer analgesics

EurekAlert!
LSU Health New Orleans discovers new class of safer analgesics
July 6, 2020

Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys. The research is published online in the European Journal of Medicinal Chemistry. Current drugs have unwanted side effects. Opioids can not only cause addiction; recent studies have shown they can be no more effective at relieving pain than non-narcotic drugs. Non-steroidal anti-inflammatories (NSAIDs) can cause kidney damage. Acetaminophen is an effective drug, but overuse can result in liver damage.

Read more here

LSU Health New Orleans Discovers New Class of Safer Analgesics

Jul 6, 2020

Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys. The research is published online in the European Journal of Medicinal Chemistry.

Current drugs have unwanted side effects. Opioids can not only cause addiction; recent studies have shown they can be no more effective at relieving pain than non-narcotic drugs. Non-steroidal anti-inflammatories (NSAIDs) can cause kidney damage. Acetaminophen is an effective drug, but overuse can result in liver damage.

The research team, led by Drs. Hernan A. Bazan, a professor in the Department of Surgery and Program Director of the Vascular Surgery Fellowship at Ochsner Clinic, and Surjyadipta Bhattacharjee, a post-doctoral researcher at the LSU Health New Orleans Neuroscience Center of Excellence, set out to discover what causes the liver damage associated with

Read more here

New class of safer analgesics discovered

ScienceDaily
New class of safer analgesics discovered
July 6, 2020

Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys. The research is published online in the European Journal of Medicinal Chemistry. Current drugs have unwanted side effects. Opioids can not only cause addiction; recent studies have shown they can be no more effective at relieving pain than non-narcotic drugs. Non-steroidal anti-inflammatories (NSAIDs) can cause kidney damage. Acetaminophen is an effective drug, but overuse can result in liver damage.

Read more here

Safer Non-Opioid Pain Relief on the Horizon: SRP-001 Shows Promise in Phase 1 Trials

Health & Pharma
Safer Non-Opioid Pain Relief on the Horizon: SRP-001 Shows Promise in Phase 1 Trials
May 23, 2024

With FDA Fast Track designation, the new non-opioid pain medication SRP-001 shows promising Phase 1 trial results, offering a safer alternative for pain management. Unlike traditional painkillers, SRP-001 does not pose risks of abuse, liver, or kidney damage and effectively targets pain via AM404 in the brain’s PAG region.

Read more here

Novel Non-Addictive, Non-Toxic Painkiller Developed at LSU Health New Orleans

LSU Health New Orleans
Novel Non-Addictive, Non-Toxic Painkiller Developed at LSU Health New Orleans
May 16, 2024

LSU Health New Orleans announces the discovery and clinical advancement of a new non-opioid therapeutic candidate for treatment of acute, chronic, and neuropathic pain and migraine headaches which does not have the organ toxicity or addiction potential of other currently-available pain therapeutics.

Read more here

Ochsner Health physician granted NIH Trailblazer Award

Eureka Alert!
Ochsner Health physician granted NIH Trailblazer Award
February 14, 2024

In response to the pressing need for new pain treatments during the opioid crisis, the National Institutes of Health (NIH) has honored Dr. Hernan Bazan, an Ochsner Health physician and John Ochsner Endowed Professor of Cardiovascular Innovation, with the 2024 NIH Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative® Director’s Trailblazer Award.

Read more here

Global Business Report

Global Business Reports
Global Business Report
October 17, 2023

Can you give an overview of South Rampart Pharma and present SRP-001? South Rampart Pharma is a clinical-stage, phase 1 life science company developing a best-in-class new chemical entity (NCE), SRP-001, a non-opioid small molecule analogous to acetaminophen or paracetamol. The significant differentiator is that it does not have the liver toxicity of acetaminophen /paracetamol/Tylenol or the kidney toxicity of NSAIDs like ibuprofen.

Read more here

Warning About Potential Risks from Overuse of Acetaminophen with Karen Smith Catie’s Cause

Empowered Patient Podcast with Karen Jagoda
Warning About Potential Risks from Overuse of Acetaminophen with Karen Smith Catie’s Cause
June 5, 2023

Karen Smith is the Founder of Catie’s Cause, a nonprofit charity dedicated to building awareness about the safe use of over-the-counter pain medications. After the death of her daughter Catie from liver failure due to overuse of Tylenol, Karen founded this organization to shine a light on the unintended and intentional side effects of easy access to these medicines.

Read more here

Biotechnology Innovation Organization – I am BIO Podcast

Biotechnology Innovation Organization – I am BIO Podcast
Episode 80: Cracking the Code on Pain Relief
February 28, 2023

Imagine living with excruciating pain that prevents you from walking or doing the things most of us take for granted. We all experience pain, and 50 million people cope with chronic, debilitating pain. The market for pain therapies is estimated at $74 billion. And yet, investment in new pain and addiction treatments is falling short of what is needed, according to a new BIO report, which shows a 44% decrease in clinical drug programs for pain over the past five years. Our guests on this episode talk about the challenges of living with and treating pain, as well as research and development on new, non-addictive and safer pain therapies.

Read more here

BIO CEO 2023: Despite high prevalence of pain and addiction, clinical efforts drop, funding flat, BIO report finds

BioWorld
BIO CEO 2023: Despite high prevalence of pain and addiction, clinical efforts drop, funding flat, BIO report finds
Feb. 9, 2023

The Biotechnology Innovation Organization (BIO) found in a new study that 77% of clinical programs focused on pain
therapeutics five years ago are no longer active and that financings of companies working in the space are lackluster at
best.

Meanwhile, oncology companies, targeting an overall smaller market, have raised huge sums of venture capital (VC)
money, $9.7 billion in 2021 vs. pain and addiction companies’ $228 million.

Read more here

Focus and Fundamentals: CFO Strategies on the Journey to Commercialization

Pharmaceutical Executive
Focus and Fundamentals: CFO Strategies on the Journey to Commercialization
February 9, 2023

Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day.

On Dec. 1, 2022, a panel consisting of chief financial officers (CFOs) and other financial experts convened for a virtual roundtable to discuss the recent economic developments in the life sciences industry and how companies are adapting. The biopharmaceutical sector has not been immune to global economic challenges. After the COVID-19 pandemic generated a wave of new interest in the life sciences, the past year saw a retraction in the market.

Read more here

Founders Keepers podcast

Founders Keepers podcast
#35 Conference Special (2/2): Dr Hernan Bazan from South Rampart Pharma
February 9, 2023

Founded in 2016, South Rampart Pharma is a clinical-stage life science company dedicated to advancing the safe treatment of pain by developing new non-opioid small molecule solutions that lack the liver and kidney toxicity present in current pain medicines. The company’s lead program, SRP-001, is currently in a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics with data expected later this year in 2023.

Read more here

Panel Takes on Challenges in Pain Therapeutics at BIO CEO

BioSpace
Panel Takes on Challenges in Pain Therapeutics at BIO CEO
February 9, 2023

Finding long-term, non-addictive solutions to manage chronic pain in the U.S. has long been a challenge for biopharma. In thefallout from the opioid pandemic, physicians and researchers are scrambling for options.

Tuesday, a panel of experts took on stiff questions about pain/addiction therapeutics during a panel hosted by theBiotechnology Innovation Organizaion (BIO) in New York City.

Read more here

‘All hands on deck’ needed to address U.S. pain and addiction innovation

Bio.News
‘All hands on deck’ needed to address U.S. pain and addiction innovation
February 8, 2023

The number of new pain drugs in the development pipeline has slowed to a trickle and investment in addiction drugs is low, challenges addressed during an impassioned, collaborative panel, “Resetting the innovation landscape for pain and addiction therapeutics,” yesterday at BIO’s 2023 CEO and Investor Conference.

Panelists discussed potential solutions as they responded to BIO’s recent report, “The State of Innovation in Pain and Addiction,” which describes the issue in detail.

Read more here

Scrip Asks…What Does 2023 Hold For Biopharma? Part2: M&A And Partnering

Scrip Pharma Intelligence
Scrip Asks…What Does 2023 Hold For Biopharma? Part2: M&A And Partnering
January 9, 2023

Hernan Bazan, CEO of South Rampart Pharma, which is developing small molecules for pain relief, also commented on the benefits of in-person get-togethers, although he acknowledged the perks of virtual interaction when it comes to partnering. “I think hybrid approaches will continue in 2023. Following the pandemic, my first in-person partnering meeting was BIO in June 2022 (San Diego), and there was palpable excitement to meet face-to-face. Though deals can be done virtually, personal interaction allows a connection to be made when technology and partnering tactics are discussed. Virtual meeting platforms allow for efficient use of time when doing more technical reviews,” he said.

“For these reasons, I feel the hybrid approach is here to stay. I think partnering through option license deals for promising technologies – particularly those with clinically

Read more here

Current Lack of Innovation in the Pain Space Hurts Society

MedCity News
Current Lack of Innovation in the Pain Space Hurts Society
December 22, 2022

The future towards the safer treatment of pain will come as biopharma, and investor communities appreciate the significant opportunities in supporting scientifically rigorous and clinically validated lead assets for the safer treatment of pain.

Current pain medications are addictive (opioids), or potentially damaging to the liver (acetaminophen/Tylenol or kidneys with substantial gastrointestinal toxicity (nonsteroidal anti-inflammatory drugs, NSAIDs).

Read more here

Tales From the 2022 Biotech VC Fundraising Trail

The Wall Street Journal
Tales From the 2022 Biotech VC Fundraising Trail
December 22, 2022

After the bonanza of 2021, life-sciences entrepreneurs reset their expectations as financing contracted

Biotechnology entrepreneurs recalibrated in 2022 as their financing options narrowed, a reversal from years in which life-sciences startups were flush with capital.
With just two weeks left in the year, U.S. biotechs had raked in $29.7 billion for 2022, compared with the record—$38.7 billion—deployed in all of 2021, according to market tracker PitchBook Data Inc.

Read more here

Wellbeing Checkup

Medical World News
Wellbeing Checkup
December 9, 2022

It is estimated that up to 20% of US adults are dealing with chronic pain and 8% of US Adults have high-impact chronic pain. Dr. Hernan Bazan discusses the issues associated with suffering from chronic pain and daily use of opioids, offers some insights on traditional pain relievers, and how the next generation of therapies in development need to be a safe, potential alternative from opioids.

Read more here

Non-toxic and addiction free: The promise of a new pain med

PharmaVoice
Non-toxic and addiction free: The promise of a new pain med
December 2, 2022

Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

Pain relief without toxicity or addiction could become a reality, and South Rampart Pharma’s father-son, surgeons-turned-entrepreneurs duo could hold the key. Dr. Hernan Bazan, CEO and co-founder of the clinical stage pain company, believes it’s on the right track to capitalize not only on a market that is predicted to be valued at $90 billion by 2026, but help the 20% of adults worldwide who suffer from chronic pain.

Read more here

A New Pain Treatment Requires Accurate And Reliable Data, South Rampart Pharma on Featured on Clinical Leader piece.

Clinical Leader
A New Pain Treatment Requires Accurate And Reliable Data, South Rampart Pharma on Featured on Clinical Leader piece.
September 22, 2022

South Rampart Pharma aims to deliver a new, affordable treatment for pain that will avoid the issues with currently marketed products. Opioids are highly addictive; patients taking excessive amounts of acetaminophen can develop liver toxicity; and NSAID over-exposure risks kidney toxicity, gastrointestinal (GI) bleeding, and worsening of high blood pressure in patients with hypertension.

Read more here

South Rampart Pharma Hopes to Develop Safer Pain Medications

Biz New Orleans
South Rampart Pharma Hopes to Develop Safer Pain Medications
June 14, 2022

South Rampart Pharma, a clinical-stage life science company advancing medications for the treatment of pain and fever, announced it achieved milestones outlined in the Phase I portion of its Small Business Technology Transfer (STTR) grant (1R42NS119103) received from the National Institutes of Health (NIH) and advanced to the Phase II portion of its NIH grant. The “fast-track” combined Phase I/II award provides for $1.9 million of funding to support the ongoing clinical development of the company’s lead small molecule, SRP-3D (DA), a novel non-opioid therapeutic candidate. South Rampart Pharma currently is completing the single ascending dose phase of the Phase 1 clinical trial of SRP-3D (DA) and remains on track to report topline results from the study in the third quarter of 2022.

Read more here

South Rampart Pharma Invited to Participate in 2021 NIH Innovation Conference & Life Sciences Summit

NOLABA News
South Rampart Pharma Invited to Participate in 2021 NIH Innovation Conference & Life Sciences Summit
August 20, 2021

Exciting news for local company South Pharma! They’ve been selected to participate in the 2021 NIH Innovation Conference (NIC – a half-day, virtual event on Monday, Oct. 4) and Life Science Summit (LSS – a two-day virtual event Tuesday, Nov. 9 and Wednesday, Nov. 10) that connects innovation, capital, and industry.

See Q&A below with Company co-founder Dr. Hernan A. Bazan.

How do you feel about being selected to participate in the NIH Conference?

It’s obviously a great recognition of the hard science behind the venture.  In 2020 we were able to compete with top groups from the major academic and entrepreneurial centers around the U.S. and an NIH (NINDS) Commercialization grant we submitted was scored highly and was funded.  The NIH leadership has seen the progress in the past year and has

Read more here

LSU HSCNO Spin-Out Awarded $1.9M in STTR Fast Track Funding

LSU Health New Orleans
LSU HSCNO Spin-Out Awarded $1.9M in STTR Fast Track Funding
September 28, 2020

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer (STTR) grant to South Rampart Pharma. The New Orleans life science company is developing a new class of non-opioid medicines to relieve pain and reduce fever discovered at and licensed from LSU Health New Orleans, its formal collaborating research institution.

Read more here

NIH Awards $1.9 million STTR Grant to Fast Track New Class of Non-Opioid Pain Relievers

News-Medical.Net
NIH Awards $1.9 million STTR Grant to Fast Track New Class of Non-Opioid Pain Relievers
September 25, 2020

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer (STTR) grant to South Rampart Pharma. The New Orleans life science company is developing a new class of non-opioid medicines to relieve pain and reduce fever discovered at and licensed from LSU Health New Orleans, its formal collaborating research institution.

Read more here

Novel Analgesic for Pain Relief Lacks Liver Toxicity

PainRelief.com
Novel Analgesic for Pain Relief Lacks Liver Toxicity
July 24, 2020

Thank you for your kind invitation and opportunity to commend on our paper in press in the European Journal of Medicinal Chemistry entitled ‘A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis.’ This is the culmination of a multi-disciplinary effort involving investigators from the United States in Spain in search for a solution to the problem of treating pain more safely.

Read more here

Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects

AJMC
Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects
July 20, 2020

The coronavirus disease 2019 pandemic presents a new challenge: patients have severe flu-like symptoms, but the virus can also cause renal failure. Doctors and patients need analgesics that go easy on the liver and kidneys but are not addictive, and this week researchers at LSU Health New Orleans Neuroscience Center of Excellence announced they have discovered a new class of drugs that can do the job.

Read more here

South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication

BioSpace
South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication
July 14, 2020

South Rampart Pharma, LLC (“South Rampart” or “the Company”), a company committed to improving the lives of people suffering from pain by developing a new class of non-opioid pain medicines, today announced a peer-reviewed publication detailing the identification and characterization of a new class of compounds able to reduce pain and fever without abuse potential or the liver and kidney toxicity associated with over the counter pain medicines such as acetaminophen.

Read more here

Research Roundup: COVID-19 Immunity, Stomach Acid Susceptibility and More

BioSpace
Research Roundup: COVID-19 Immunity, Stomach Acid Susceptibility and More
July 10, 2020

Investigators at LSU Health New Orleans Neuroscience Center of Excellence identified a new class of pipeline drugs to relieve pain and reduce fever. Furthermore, they appear to have decreased risk of addiction or damage to the liver or kidneys. In two models, the drugs, which are similar to acetaminophen, but do not appear to damage the liver or kidneys, decreased pain and reduced fever. The intellectual property has been licensed from LSU to the life science startup South Rampart Pharma, which is working to develop the drug in late preclinical development.

Read more here

Novel class of non-addictive analgesics demonstrate safety in animals

Drug Target Review
Novel class of non-addictive analgesics demonstrate safety in animals
July 7, 2020

To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen. Acute and chronic pain management is a growing global health burden. With the opioid epidemic still on the rise, and nephro- and hepatotoxicity linked to prolonged use of non-narcotic pain medications, novel analgesics (pain killers) are desperately needed.

Read more here

A new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage

Innovation Toronto
A new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage
July 6, 2020

Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys. The research is published online in the European Journal of Medicinal Chemistry.

Read more here

LSU Health New Orleans discovers new class of safer analgesics

EurekAlert!
LSU Health New Orleans discovers new class of safer analgesics
July 6, 2020

Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys. The research is published online in the European Journal of Medicinal Chemistry. Current drugs have unwanted side effects. Opioids can not only cause addiction; recent studies have shown they can be no more effective at relieving pain than non-narcotic drugs. Non-steroidal anti-inflammatories (NSAIDs) can cause kidney damage. Acetaminophen is an effective drug, but overuse can result in liver damage.

Read more here

New class of safer analgesics discovered

ScienceDaily
New class of safer analgesics discovered
July 6, 2020

Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys. The research is published online in the European Journal of Medicinal Chemistry. Current drugs have unwanted side effects. Opioids can not only cause addiction; recent studies have shown they can be no more effective at relieving pain than non-narcotic drugs. Non-steroidal anti-inflammatories (NSAIDs) can cause kidney damage. Acetaminophen is an effective drug, but overuse can result in liver damage.

Read more here

South Rampart Pharma Publishes SRP-001’s Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports

May 16, 2024

  • SRP-001 is a novel, non-opioid new chemical entity without abuse, liver, and kidney toxicities present in current pain medications
  • Publication introduces SRP-001 as a safer alternative to existing pain medications
  • SRP-001 triggers N-arachidonoylphenolamine (AM404) formation in the midbrain’s periaqueductal grey (PAG) region, a potent activator of TRPV1 that plays a crucial role in the brain’s response to pain
  • FDA awarded SRP-001 Fast Track designation for acute pain in October 2023
  • Phase 1 trial shows SRP-001 is safe and well-tolerated with favorable pharmacokinetics making it Phase 2-ready for the treatment of neuropathic pain, acute/chronic pain, and patients with acute migraine headaches.
  • A Phase 2 trial in acute pain will launch in the second half of 2024

NEW ORLEANS, May 16, 2024 (GLOBE NEWSWIRE) — South Rampart Pharma, Inc., today announced the publication of a paper in Scientific Reports describing the manner in which SRP-001 works

Read more here

South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and Acute Pain Trials

January 2, 2024

Phase 1 data demonstrate that SRP-001 exhibits an exceptionally strong safety and robust pharmacokinetic profile and is well-tolerated
Well-designed Phase 2 trials set to show statistical significance compared to placebo and positive control

 

New Orleans, LA, January 2, 2024 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company focused on developing innovative pain treatments, announced today that it has successfully completed a Phase 1 trial (NCT05484414). The Phase 1 randomized clinical trial (RCT) of SRP-001, a first-in-class analgesic targeting the midbrain’s PAG region, was a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and pharmacokinetics (PK) of SRP-001 in healthy subjects. Conducted in collaboration with Quotient Sciences in Miami, Florida, the trial’s completion marks a significant milestone, as SRP-001 has now received U.S. FDA Fast-Track designation, underscoring its potential in the safe and effective treatment of pain.

The demand for

Read more here

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

November 1, 2023

South Rampart’s Global Intellectual Property Portfolio Now Includes Patents in Key Markets: United States, Europe, Greater China, India, Japan, S. Korea, Australia, Canada, Brazil, Russia, and Mexico

 

New Orleans, LA, November 1, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company focused on developing innovative pain treatments,

announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

The patent, entitled “Compositions and methods for ameliorating pain,” encompasses the methods and composition of matter for a library of novel non-opioid small molecules devoid of liver toxicity for acute, chronic, and neuropathic pain. This includes the Company’s lead clinical candidate, SRP-001, which the U.S. FDA granted Fast Track designation for acute pain on October 9, 2023, and is ending Phase

Read more here

South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain

Oct. 12, 2023

The Fast Track designation accelerates SRP-001’s path to U.S. FDA submission for the treatment of acute pain

Enhanced time-to-market delivers a therapeutic alternative to habit-forming opioids and acetaminophen, the leading cause of acute liver failure in the U.S.

NEW ORLEANS, Oct. 12, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage biopharmaceutical company targeting the safer treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company for SRP-001 for the treatment of acute pain. SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain’s periaqueductal grey (PAG) region without liver and kidney toxicities. The Fast Track designation facilitates the development and expedites the review of new therapies for serious conditions, aiming to bring important new drugs to patients earlier and

Read more here

South Rampart Pharma to Participate in Upcoming Investor Events

October 10, 2023

 – BIO Investor Forum taking place on October 17-18, 2023 –

 – The 17th Annual Pain Therapeutics Summit taking place on October 19-20, 2023

 

New Orleans, LA, October 10, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company developing SRP-001, a first-in-class non-opioid candidate for the treatment of chronic and acute pain, today announced the Company’s executive team will be participating in the upcoming investor events throughout October 2023:

 

BIO Investor Forum (San Francisco, CA):

Date: October 17-18, 2023

Corporate Presentation Time: 2:15 PM ET, Oct. 17, 2023

Title: ‘‘SRP-001, A First-in-Class, Non-Opioid Analgesic Targeting Novel Pain Signaling Pathways in the Periaqueductal Grey Region: Phase 1 Interim Results & Comparative Efficacy.”

Panel Discussion: 5:00 PM ET, Oct. 17, 2023

Title: “Succeeding at Technology Transfer:  Best Practices for Industry-Academia Collaboration.”

Program: https://bif.bio.org/program

South Rampart’s Co-founder and CEO, Dr. Hernan Bazan, will present a Corporate

Read more here

South Rampart Pharma Awarded Second NIH Grant for Commercialization Readiness Pilot Program

Sept. 21, 2023

The NIH’s CRP Award Further Validates the Business Case and Commercial Opportunity of
SRP-001 as a First-in-Class Non-narcotic Analgesic for Acute and Chronic Pain

NEW ORLEANS, Sept. 21, 2023 — South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that it has been awarded The Commercialization Readiness Pilot Program (CRP) grant by the National Institute of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) for its application entitled ‘Novel non-narcotic analgesic for acute and chronic pain.’ This grant under award number 2SB1NS119103–04 propels select biotech firms towards market readiness, bolstering South Rampart’s mission to foster advancements in the safer treatment of pain management through novel non-narcotic solutions. Today’s announcement follows the Company’s earlier receipt of the NIH’s Fast-Track Small Business Technology Transfer (STTR) Commercialization

Read more here

South Rampart Pharma Announces First Patient Enrolled in Multiple Ascending Dose Portion of Ongoing Phase 1 ClinicalTrial

August 22, 2023

– SRP-001, a novel, non-opioid investigational drug that avoids the liver toxicity associated with acetaminophen, positioned to address the unmet medical need for non-toxic and non-addictive acute and chronic pain therapeutics –

– Data expected in 3Q 2023 –

New Orleans, LA, Aug 22, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the first patient of its Phase 1 trial, multiple ascending dose (MAD) study, has been dosed. The primary objective of the MAD study is to assess the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of oral SRP-001 to healthy male and female volunteers, with the primary endpoints being safety and tolerability by assessing adverse events (AEs), vital signs, electrocardiograms (ECGs), physical examinations, laboratory safety tests, and select PK/PD parameters. The trial is expected to be completed in

Read more here

South Rampart Pharma Further Expands Patent Portfolio for SRP-001 with Composition of Matter Patent in China

July 6, 2023

South Rampart’s global intellectual property portfolio now includes granted patents in the United States, China, India, Japan, Australia, Canada, Brazil, Russia, and Mexico

New Orleans, LA, July 6, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of SRP-001, South Rampart’s novel, non-opioid new chemical entity that avoids the liver toxicity associated with acetaminophen. The Company is currently developing SRP-001 for treating acute and chronic pain and is evaluating it in an ongoing Phase 1 trial. This patent, as well as other patents the Company has been granted and is currently pursuing, is a key part of South Rampart’s global intellectual property (IP) and patent strategy.

The Chinese Patent Office issued

Read more here

South Rampart Pharma to Present at 2023 BIO CEO & Investor Conference

Jan. 31, 2023

Hernan Bazan, MD, FACS, CEO and Co-Founder, will provide a company update

Dr. Bazan will also participate in a panel on pain therapeutics innovation with a VP of Industry Research from BIO and Program Directors from NIH and the U.S. Pain Foundation

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative non-opioid medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at the BIO CEO & Investor Conference on Monday, February 6.

Dr. Bazan’s presentation will highlight the recent company developments on its novel non-opioid lead asset, ongoing pipeline progress, clinical trial updates and anticipated milestones. Details about the presentation are as follows:

Presenter: Hernan Bazan, MD, FACS,

Read more here

South Rampart Pharma Announces Presentation at Arrowhead’s 16th Annual Pain Therapeutics Summit

Oct. 21, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at Arrowhead’s 16th Annual Pain Therapeutics Summit.

Taking place in Washington, DC, on November 14-15, 2022, the Pain Therapeutics Summit is the US’s premier conference covering pain research and emerging therapeutics. Leaders from the biopharmaceutical industry, academia, and the NIH attend the conference to learn about the latest advances in treating various kinds of pain and network with colleagues from industry, academia, clinical research organizations, and government.

Dr. Bazan’s presentation, “Overcoming the Liver Toxicity Associated with Acetaminophen Via a New Class of Small Molecule Non-Opioids,” will highlight the ongoing clinical development of novel non-opioid small molecule SRP-001 for the treatment

Read more here

South Rampart Pharma Issued Composition of Matter Patent for Novel Non-Toxic Treatment for Pain

Oct. 4, 2022

 New patent grant further secures South Rampart’s competitive position in next-generation and disruptive investigational drugs for acute pain –

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced the issuance of a composition of matter US patent No. 11,458,142 for its novel, non-opioid, and non-liver toxic treatments for pain. The issued patent covers a library of novel small molecules, including the Company’s lead program, SRP-001, which is currently being studied in a two-part randomized, double-blind, placebo-controlled study Phase 1 study evaluating safety, tolerability, and pharmacokinetics, with data expected early in 2023.

This issued patent adds to the Company’s growing patent portfolio, which includes ‘Compositions and methods for ameliorating pain and reducing fever’ US patent No. 11,007,199. The Composition of Matter patent issued today has been nationalized in key world markets. South

Read more here

South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant

Sept. 22, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that it received a Notice of Award from the National Institutes of Health (NIH) regarding Year 3 of its Small Business Technology Transfer (STTR) grant.

The NIH grant is entitled ‘Novel non-narcotic analgesic for acute and chronic pain.’ South Rampart Pharma will receive the Year 3 incremental Award of the $1.9M grant administered through the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), which will continue to help support the development of SRP-001, the Company’s lead drug candidate.

SRP-001 is a novel, non-opioid small molecule with the potential to overcome many risks associated with current pain medicines, including the liver toxicity of acetaminophen. Importantly, SRP-001 mirrors acetaminophen’s clinically validated mechanism of action while simultaneously muting the biological activity that causes liver toxicity. South Rampart Pharma is

Read more here

South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain

Aug. 25, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that the Company will present a late-breaking abstract at the International Association for the Study of Pain (IASP) 2022 World Congress on Pain, which will take place on September 20-23, 2022, in Toronto, Canada.

The late-breaking presentation, entitled “Novel Non-Opioid Analgesic for Acute and Chronic Pain: From Discovery to Phase 1 Trial,” will chronicle the invention and development of SRP-001 (previously known aSRP-3D (DA)). Central to SRP-001’s therapeutic differentiation, this non-opioid investigational pain medication exhibits comparable, if not better, efficacy as similar approved drugs but notably does not exhibit their liver or kidney toxicity. South Rampart’s CEO and Co-founder, Hernan Bazan, MD, FACS, will deliver the presentation.

“I’m delighted to have this opportunity to showcase the groundbreaking work we’ve done with SRP-001,” commented Dr. Bazan. “Liver toxicity

Read more here

South Rampart Pharma Announces Appointment of Josh Blacher as Chief Financial Officer

Aug. 16, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced the appointment of Josh Blacher as the company’s Chief Financial Officer. In this capacity, Mr. Blacher will be responsible for the Company’s finance and accounting department, as well as launch a robust corporate development effort.

Mr. Blacher brings to South Rampart Pharma over twenty years of leadership experience in senior positions in the healthcare and capital markets sectors. Hernan Bazan, M.D., F.A.C.S., CEO and Co-Founder of South Rampart Pharma and The Endowed John Ochsner Professor of Surgery at the Ochsner Clinic, commented, “We are thrilled to welcome Josh to our team. Josh brings us a valuable combination of executing growth capital initiatives as well as strategic collaborations with biopharmaceutical partners.” Dr. Bazan continued, “As we ready for Phase 2 clinical trials of our novel non-opioid

Read more here

South Rampart Pharma Achieves Development Milestone and Advances to Phase II of Active NIH Fast-Track STTR Commercialization Award

May 4, 2022

$1.9 million NIH fast-track STTR grant fuels next stage of clinical program dedicated to the development of a novel non-opioid approach to pain management

Lead program SRP-3D (DA) advances in ongoing Phase 1 clinical trial with data expected in the third quarter of 2022

 

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced it achieved milestones outlined in the Phase I portion of its Small Business Technology Transfer (STTR) grant (1R42NS119103) received from the National Institutes of Health (NIH) and advanced to the Phase II portion of its NIH grant. The ‘fast-track’ combined Phase I/II award provides for $1.9 million of funding to support the ongoing clinical development of the Company’s lead small molecule, SRP-3D (DA), a novel non-opioid therapeutic candidate. South Rampart Pharma currently is completing the single

Read more here

South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)

March 23, 2022

SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications

Potential to address the significant unmet need for new, safe, effective, and non-opioid pain medications

Development program funded by the National Institutes of Health (NIH) through a Small Business Technology Transfer (STTR) Fast Track Grant

Topline results expected Q3 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company focused on advancing innovative medications for the treatment of pain and fever, announced today patient enrollment and dosing in its Phase 1 study evaluating SRP-3D (DA) for pain is underway.

“We are committed to improving the lives of people suffering from acute, chronic, or neuropathic pain by developing a new class of small molecule, non-opioid pain medicines. To date, SRP-3D (DA) has shown promising efficacy in reducing both pain and fever while lacking the liver and kidney toxicity associated

Read more here

NIH STTR Grant To Fast Track New Class Of Pain Reliever Without Addiction Or Toxicity

Sep 25, 2020

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer (STTR) grant to South Rampart Pharma. The New Orleans life science company is developing a new class of non-opioid medicines to relieve pain and reduce fever discovered at and licensed from LSU Health New Orleans, its formal collaborating research institution.

The grant will fund late-stage, pre-clinical development of the new analgesic/antipyretic and will also support continued collaboration with LSU Health New Orleans Neuroscience Center of Excellence on pain mechanisms. A paper describing the patented new drug was recently published in the European Journal of Medicinal Chemistry.

“The safe treatment of acute and chronic pain is one of the most prevalent and costly public health issues worldwide,” said Hernan Bazan, MD, DFSVS, FACS, CEO and co-founder of South Rampart Pharma, and Professor of Surgery at the Ochsner

Read more here

South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication

July 10, 2020

South Rampart Pharma, LLC (“South Rampart” or “the Company”), a company committed to improving the lives of people suffering from pain by developing a new class of non-opioid pain medicines, today announced a peer-reviewed publication detailing the identification and characterization of a new class of compounds able to reduce pain and fever without abuse potential or the liver and kidney toxicity associated with over the counter pain medicines such as acetaminophen. The paper, published in the European Journal of Medicinal Chemistry, is available as open access and entitled, “A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis1.

“We are currently working to finalize the preclinical data package necessary to submit our lead molecule for the first Investigational New Drug (IND) application by the third quarter of 2020, followed by the rapid initiation of Phase 1 clinical trials to evaluate safety. Ongoing preclinical studies have

Read more here

LSU Health New Orleans Discovers New Class of Safer Analgesics

Jul 6, 2020

Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys. The research is published online in the European Journal of Medicinal Chemistry.

Current drugs have unwanted side effects. Opioids can not only cause addiction; recent studies have shown they can be no more effective at relieving pain than non-narcotic drugs. Non-steroidal anti-inflammatories (NSAIDs) can cause kidney damage. Acetaminophen is an effective drug, but overuse can result in liver damage.

The research team, led by Drs. Hernan A. Bazan, a professor in the Department of Surgery and Program Director of the Vascular Surgery Fellowship at Ochsner Clinic, and Surjyadipta Bhattacharjee, a post-doctoral researcher at the LSU Health New Orleans Neuroscience Center of Excellence, set out to discover what causes the liver damage associated with

Read more here

Go to Top